MAMichelle A. Albert

Michelle A. Albert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle A. Albert has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis

    by Michelle A Albert, Nader Rifai, Paul M Ridker

    Cystatin-C, a cysteine protease inhibitor, and mannose binding lectin, an innate defense protein involved in microbial clearance, have both been hypothesized to mediate atherosclerotic plaque progression. Prospective data evaluating whether levels of these proteins are associated with incident cardiovascular disease are sparse. Employing a prospective, nested, case-control study design, baseline levels of cystatin-C and mannose binding protein were evaluated among 133 apparently healthy men who subsequently developed symptomatic peripheral arterial disease (cases) and among 133 age- and smoking-matched controls who remained free of reported vascular disease during 5 years of follow-up. Overall, median baseline levels of cystatin-C were virtually identical among case and control subjects (0.83 mg/l, p = 0.84), whereas median baseline levels of mannose binding protein among cases and controls were 2.32 mg/l and 2.20 mg/l respectively (p = 0.69). No evidence of association was found between either cystatin-C or mannose binding protein and the development of peripheral arterial disease in analyses evaluating for linear trends or for threshold effects (all p-values ≤ 0.05). In contrast with prior retrospective and cross-sectional studies, no evidence was found that baseline levels of cystatin-C or mannose binding protein are associated with an increased risk of future arterial disease.


  • The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design

    by Michelle A. Albert, Joan Staggers, Paul Chew, Paul M. Ridker


  • The role of C-reactive protein in cardiovascular disease risk

    by Michelle A. Albert

    Over the past few years, a flurry of data in the medical literature has strongly implicated C-reactive protein (CRP) as a marker of inflammation in coronary artery disease (CAD). Recognizing the likely integral role that inflammation plays in the pathogenesis of atherosclerosis, many hospital laboratories have tests to measure CRP concentration in the clinical setting. However, the clinical use of these tests still need definition. To date, of the plasma-based markers investigated, CRP provides the strongest risk prediction for cardiovascular disease in men and women. Questions remain regarding the degree to which CRP can improve risk stratification beyond that of the traditional risk factors of CAD.